Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-877 Drug Interaction Study
NCT04138836Phase 1Completed
- Sponsor
- Bridge Biotherapeutics
- Start
- Sep 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LCB17-0877 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Bridge Biotherapeutics. Primary endpoints: Area Under the Curve at Day 10 and Peak Plasma Concentration at Day 10. Started Sep 2019; status: completed.
02
Drugs
LCB17-0877
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04138836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138836.